Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.


TSXV:THRM - Post by User

Post by forrest6748on Apr 28, 2022 8:25am
212 Views
Post# 34638170

NEWS: Therma Bright Ships Initial Venowave Order to US Distr

NEWS: Therma Bright Ships Initial Venowave Order to US Distr

Therma Bright Ships Initial Venowave Order to US Distributor

Toronto, Ontario--(Newsfile Corp. - April 28, 2022) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company and developer of the AcuVid™ Covid-19 Rapid Antigen Saliva Test, is pleased to announce that the initial order of its updated Venowave product has been shipped to its US distributor, DME Authority, LLC, from Therma's Chinese contract manufacturer. As previously announced on December 16, 2021 the initial order consists of 2,500 units, each unit consists of 2 Venowave devices, of which 500 units have been shipped by air, with the balance being shipped by sea.

Despite the challenges of material and component shortages, logistics and shipping delays and lockdowns in various parts of China, the initial order was completed and shipped recently.

Venowave is a compact and lightweight Deep Vein Thrombosis (DVT) prevention pump specifically designed for use at home. The Venowave device uses a continuous wave motion to increase blood flow in the veins. The increased blood circulation helps prevent venous stasis, which is a major contributor in thrombus formation. Specifically, the device imitates the body's venous system to counteract the pooling of blood in the lower extremities which can lead to clotting. With about 50% of DVTs beginning to form intra-operatively and 75% forming within 48 hours post-operatively, this technology is pioneering an alternative, easy to use life-saving treatment for this condition.

Rob Fia, CEO stated "We are pleased to have the first shipments of our Venowave product sent to DME Authority, our US distributor. It has been a frustrating process with all of the shortages and delays, but we are now poised to increase production and availability of the product as demand grows. We are excited to be able to deliver products to customers in the US who have been patiently waiting for this potential life saving technology."

<< Previous
Bullboard Posts
Next >>